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Recombinant attenuated 
Salmonella Typhimurium with 
heterologous expression of 
the Salmonella Choleraesuis 
O-polysaccharide: high 
immunogenicity and protection
Xinxin Zhao1,2,3, Qinlong Dai3, Dekang Zhu1,2,3, Mafeng Liu1,2,3, Shun Chen1,2,3,  
Kunfeng Sun1,2,3, Qiao Yang1,2,3, Ying Wu1,2,3, Qingke Kong3,4 & Renyong Jia1,2,3
Non-typhoidal Salmonella are associated with gastrointestinal disease worldwide and invasive disease 
in Africa. We constructed novel bivalent vaccines through the recombinant expression of heterologous 
O-antigens from Salmonella Choleraesuis in Salmonella Typhimurium. A recombinant Asd+ plasmid 
pCZ1 with the cloned Salmonella Choleraesuis O-antigen gene cluster was introduced into three 
constructed Salmonella Typhimurium Δasd mutants: SLT11 (ΔrfbP), SLT12 (ΔrmlB-rfbP) and SLT16 
(ΔrfbP ∆pagL::TT araCPBAD rfbP). Immunoblotting demonstrated that SLT11 (pCZ1) and SLT12 (pCZ1) 
efficiently expressed the heterologous O-antigen. In the presence of arabinose, SLT16 (pCZ1) expressed 
both the homologous and heterologous O-antigens, whereas in the absence of arabinose, SLT16 (pCZ1) 
mainly expressed the heterologous O-antigen. We deleted the crp/cya genes in SLT12 (pCZ1) and 
SLT16 (pCZ1) for attenuation purposes, generating the recombinant vaccine strains SLT17 (pCZ1) and 
SLT18 (pCZ1). Immunization with either SLT17 (pCZ1) or SLT18 (pCZ1) induced specific IgG against the 
heterologous O-antigen, which mediated significant killing of Salmonella Choleraesuis and provided 
full protection against a lethal homologous challenge in mice. Furthermore, SLT17 (pCZ1) or SLT18 
(pCZ1) immunization resulted in 83% or 50% heterologous protection against Salmonella Choleraesuis 
challenge, respectively. Our study demonstrates that heterologous O-antigen expression is a promising 
strategy for the development of multivalent Salmonella vaccines.
Non-typhoidal Salmonella (NTS), a group of Gram-negative and facultative intracellular bacteria, are important 
zoonotic pathogens that cause foodborne gastrointestinal disease in humans and animals and pose a public health 
burden worldwide1, 2. It is estimated that 93.8 million cases of gastroenteritis occur due to NTS worldwide, lead-
ing to 155,000 diarrheal deaths each year3. NTS can also cause invasive diseases, such as bacteremia, septicemia 
and meningitis, with high morbidity and mortality in high risk individuals in industrialized and developing 
countries and in young children in sub-Saharan Africa4, 5. However, there is no vaccine currently available against 
NTS serovars in humans, although some O-antigen-based conjugate vaccines, live attenuated vaccines and outer 
membrane protein (OMP)-based subunit vaccines are in development.
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Exposure to animal and animal food products is one of the major risk factors resulting in human salmonello-
sis6–8. NTS comprise more than 2500 different serovars; however, relatively few restricted serovars are associated 
with bacterial transmission between animals and humans. These serovars include Salmonella enterica serovar 
Typhimurium (Salmonella Typhimurium), Salmonella Enteritidis and Group C Salmonella, such as Salmonella 
Choleraesuis and Salmonella Newport2, 9, 10. Hence, a significant burden is placed on both the animal industry and 
the healthcare system due to these bacteria. Furthermore, with the increasing frequencies of multi-drug resistant 
Salmonella strains, antibiotic treatment in human patients is becoming increasingly difficult11, 12. Thus, there is 
growing recognition that an ideal multivalent vaccine with broad coverage of epidemic serovars is needed to 
control NTS infections in both animals and humans.
The lipopolysaccharide (LPS) O-antigen, which is expressed on the outer surface of the bacterium and consists 
of oligosaccharide repeats, is the basis for the typing system of Salmonella serovars together with the flagellar 
antigen and determines the serogroup13, 14. The O-antigen is highly immunogenic and has become an impor-
tant target of protective immunity15. Passive transfer of monoclonal IgG specific to the O-antigen of Salmonella 
Typhimurium conferred protection against virulent Salmonella Typhimurium challenge16, 17. A protective 
monoclonal IgA (named Sal4) against the O-antigen of Salmonella Typhimurium could impair type 3 secre-
tion and outer membrane integrity, rendering the bacteria avirulent18. The key role of the O-antigen in protec-
tive immunity is to promote the development of O-antigen-based conjugate vaccines, such as O:9-flagellin19, 20, 
O:4,12-TT21, O:4,5/O:9-CRM19722 and Os-po23. All these conjugate vaccines have provided protection against 
virulent challenge in preclinical studies; nevertheless, they protect against only serovars with the same O-antigen 
specificity. Although cross-protection may be achieved by mixing these conjugate vaccines, the increasing cost 
of this approach is a disadvantage for application of the glycoconjugate technology24. Additionally, some atten-
uated Salmonella vaccines have exhibited cross-protective efficacy against different serovars25, 26; however, the 
cross-efficacy is limited, and only partial protection is achieved after challenge with virulent strains of heterolo-
gous serovars. Thus, there is an urgent need for novel approaches for developing a multivalent vaccine.
Live attenuated Salmonella Typhimurium has been extensively used as a vaccine vehicle to deliver heterolo-
gous antigens to the immune system and stimulate a protective immune response against a variety of targeted 
pathogens at a low cost27. A series of technologies, including the balanced-lethal vector-host systems and the 
regulated delayed in vivo attenuation, have been developed in Salmonella to improve the potency of recombi-
nant vaccines28. We hypothesized that immunization with a live attenuated Salmonella Typhimurium expressing 
heterologous O-antigens of other serovars in the outer membrane would provide both homologous and heterol-
ogous protection. The O-antigen gene cluster of Salmonella serovars responsible for O-antigen biosynthesis has 
been identified13. Here, we introduced the O-antigen gene cluster of Salmonella Choleraesuis, which resides on 
the Asd+ plasmid pCZ1, into three Salmonella Typhimurium Δasd strains: SLT11 (Δasd ΔrfbP), SLT12 (Δasd 
ΔrmlB-rfbP) and the arabinose-regulated strain SLT16 (Δasd ΔrfbP ∆pagL::TT araCPBAD rfbP), and we then 
verified the expression of the homologous and heterologous O-antigens in the three recombinant strains. Because 
Salmonella O-antigen also plays a vital role in bacterial survival and virulence29–31, we first determined the effects 
of heterologous O-antigen expression on several phenotypes, including swimming, sensitivities to polymyxin 
B and sodium deoxycholate (DOC) and colonization. We then introduced crp and cya gene mutations into the 
SLT12 (pCZ1) and SLT16 (pCZ1) strains for attenuation, and finally, we measured the immunogenicity and pro-
tective efficacy of the recombinant attenuated vaccine strains of Salmonella Typhimurium in BALB/c mice.
Results
Construction and characterization of recombinant Salmonella Typhimurium strains. The asd-
based balanced-lethal vector-host system32 was used to stably express heterologous O-antigen in Salmonella 
Typhimurium. The Asd+ plasmid pCZ1 was constructed by overlapping DNA elements, including the pSC101 
origin, asd gene cassette, TIT2 terminator, Ptrc promoter, kanamycin-resistance cassette from the plasmid 
pQK66433 and the whole O-antigen gene cluster of Salmonella Choleraesuis. Moreover, to block the synthesis of 
the Salmonella Typhimurium O-antigen, the rfbP gene (responsible for the addition of the Gal-1-phosphate res-
idue to UndP to initiate O-unit synthesis) or the whole O-antigen gene cluster (rmlB-rfbP) was deleted from the 
Salmonella Typhimurium strain SLT10 (S100 Δasd), generating SLT11 (SLT10 ΔrfbP) or SLT12 (SLT10 ΔrmlB-
rfbP), respectively. In addition, we used arabinose-dependent regulated delayed attenuation systems34, 35 to con-
struct strain SLT16 (SLT10 ΔrfbP ∆pagL::TT araCPBAD rfbP) by replacing the rfbP promoter with the araCPBAD 
promoter to ensure that the expression of homologous Salmonella Typhimurium O-antigen was activated by exog-
enous arabinose provided during in vitro growth34. Then, pCZ1 was introduced into SLT11, SLT12 and SLT16 to 
complete the construction of the three recombinant Salmonella strains SLT11 (pCZ1), SLT12 (pCZ1) and SLT16 
(pCZ1). The control strains SLT11 (pQK664), SLT12 (pQK664) and SLT16 (pQK664) were also constructed.
LPS analysis by silver staining and Western immunoblotting was employed for the parent and recombinant 
strains, which were cultured and adjusted to the same optical density before analysis. Silver staining showed that 
the Salmonella Typhimurium parent strain SLT10 and the Salmonella Choleraesuis wild-type strain S340 produced 
complete LPS ladders (Fig. 1A, lanes 1 and 6). As expected, SLT11 (pCZ1) and SLT12 (pCZ1) displayed smooth 
LPS phenotypes (Fig. 1A, lanes 3 and 5), whereas SLT11 (pQK664) and SLT12 (pQK664) displayed rough LPS 
phenotypes (Fig. 1A, lanes 2 and 4). Western immunoblotting with O:4- and O:7-specific antisera demonstrated 
that SLT12 (pCZ1) expressed the heterologous O-antigen but not the homologous O-antigen (Fig. 1B and C, lane 
5); however, unexpectedly, SLT11 (pCZ1) expressed not only the heterologous O-antigen but also short-length 
homologous O-antigen (Fig. 1B and C, lane 3). SLT16 (pCZ1) expressed O-antigens in an arabinose-dependent 
manner (Fig. 1D,E and F). In the presence of arabinose, SLT16 (pCZ1) expressed both the complete homolo-
gous and heterologous O-antigens (Fig. 1E and F, lane 4), whereas in the absence of arabinose, SLT16 (pCZ1) 
expressed the heterologous O-antigen and short-length homologous O-antigen (Fig. 1E and F, lane 5). Thus, 
SLT16 (pCZ1) displayed a chimeric O-antigen profile. In contrast, the control strain SLT16 (pQK664) expressed 
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Figure 1. LPS analysis by silver-stain and Western immunoblotting. (A,B and C). LPS extracted from 
Salmonella Typhimurium SLT10 (pQK664) (lane 1), SLT11 (pQK664) (lane 2), SLT11 (pCZ1) (lane 3), 
SLT12 (pQK664) (lane 4), SLT12 (pCZ1) (lane 5) and Salmonella Choleraesuis S340 (lane 6) was subjected 
to SDS-PAGE followed by silver staining (A) and immunoblotting analysis using O:4-specific antisera (B) 
and O:7-specific antisera (C). (D,E and F) LPS extracted from SLT10 (pQK664) (lane 1), SLT16 (pQK664) 
grown with arabinose (lane 2) or without arabinose (lane 3), SLT16 (pCZ1) grown with arabinose (lane 4) or 
without arabinose (lane 5) and S340 (lane 6) was subjected to SDS-PAGE followed by silver staining (D) and 
immunoblotting using O:4-specific antisera (E) and O:7-specific antisera (F). Each lane corresponds to LPS 
from 108 bacteria.
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homologous O-antigen but not heterologous O-antigen when grown with arabinose (Fig. 1E and F, lane 2) 
and did not express either the homologous or heterologous O-antigen when grown without arabinose (Fig. 1E and F, 
lane 3). Because SLT12 (pCZ1) expressed more heterologous antigen than SLT11 (pCZ1) (Fig. 1A, lane 3 vs lane 
5), SLT12 (pCZ1) and SLT16 (pCZ1) were used for further biological analyses.
Effects of heterologous O-antigen expression on bacterial phenotypes. Because the O-antigen 
plays an important role in Salmonella Typhimurium colonization and survival processes31, we evaluated whether 
the altered O-antigen profiles could affect bacterial phenotypes, including swimming, resistance to polymyxin B 
and DOC and colonization in vivo. As shown in Fig. 2A, the rough strains SLT12 (pQK664) and SLT16 (pQK664) 
(grown without arabinose) showed a defective swimming phenotype, while SLT12 (pCZ1), SLT16 (pQK664) 
(grown with arabinose) and SLT16 (pCZ1) (grown with or without arabinose) with the smooth LPS phenotype 
showed a similar motility capacity as the parent strain SLT10 (pQK664). A similar result was observed in exper-
iments examining resistance to polymyxin B and DOC. The strains SLT12 (pCZ1), SLT16 (pCZ1) and SLT16 
(pQK664) (grown with arabinose) exhibited comparable resistance to polymyxin B and DOC as the parent strain 
(Fig. 2B and C), while SLT12 (pQK664) and SLT16 (pQK664) (grown without arabinose) exhibited decreased 
resistance to polymyxin B and DOC (Fig. 2B and C). In addition, SLT12 (pCZ1), SLT16 (pCZ1) and SLT16 
(pQK664) displayed colonization levels in Peyer’s Patches (PP), liver and spleen of BALB/c mice that were com-
parable to the parent strain (Fig. 2D,E and F). Unexpectedly, no bacteria were detected in the three tissues after 
infection with the rough strain SLT12 (pQK664) (Fig. 2D,E and F); thus, SLT12 (pQK664) colonization was sig-
nificantly decreased compared to that of the parent strain. Therefore, our results demonstrated that heterologous 
O-antigen expression does not affect bacterial swimming, resistance to polymyxin B and DOC or colonization.
Construction of the recombinant vaccine strains and virulence evaluation. The crp and cya genes 
were deleted from SLT12 (pQK664), SLT12 (pCZ1), SLT16 (pQK664) and SLT16 (pCZ1) to attenuate virulence, 
generating the two recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1) and the two control vaccine 
strains SLT17 (pQK664) and SLT18 (pQK664). Silver staining and Western immunoblotting showed that SLT17 
(pCZ1) or SLT18 (pCZ1) displayed a similar LPS phenotype as SLT12 (pCZ1) or SLT16 (pCZ1) (Figs 1 and 3 
and Supplementary Fig. S1); the control vaccine strains SLT17 (pQK664) and SLT18 (pQK664) (grown without 
arabinose) showed rough LPS phenotypes (Fig. 3 and Supplementary Fig. S1, lanes 2 and 5). The silver staining 
also showed that SLT17 (pCZ1) expressed more heterologous O-antigens than SLT18 (pCZ1) (grown without 
arabinose) (Fig. 3, lane 3 vs lane 7). Furthermore, the 50% lethal dose (LD50) and colonization for each of the four 
vaccine strains were determined in BALB/c mice. All vaccine strains were avirulent, and their LD50 values were 
more than 2 × 109 CFU, which was > 104-fold higher than that of the wild-type strain S100 (LD50 of 5.4 × 105 
CFU) (Supplementary Table S1). The colonization levels of all of the vaccine strains in PP, liver and spleen were 
significantly decreased compared with those of the wild-type S100 strain (Supplementary Fig. S2). The vaccine 
strains SLT17 (pCZ1), SLT18 (pQK664) and SLT18 (pCZ1) retained similar capacities to efficiently colonize 
mouse tissues. In contrast, no bacteria were detected in the three tissues after infection with the control strain 
SLT17 (pQK664) (Supplementary Fig. S2).
Immunogenicity and protective efficacy of the recombinant attenuated vaccine 
strains. Seven-week-old BALB/c mice were orally immunized with PBS or approximately 109 CFU of each 
vaccine strain twice at an interval of four weeks. The mice were then challenged orally with the virulent strains 
Salmonella Typhimurium S10036 and Salmonella Choleraesuis S34036 at a dose of at least 100 × LD50 one month 
after the second immunization. Serum IgG and fecal IgA antibodies against either the homologous Salmonella 
Typhimurium or heterologous Salmonella Choleraesuis LPS were detected by enzyme-linked immunosorbent 
assay (ELISA) after immunization. No specific serum IgG antibody against either the homologous or heterol-
ogous LPS was induced after the first immunization in any of the immunized groups (Fig. 4A and B). All vac-
cine strains except SLT17 (pQK664) stimulated significantly higher levels of serum IgG and fecal IgA against 
Salmonella Typhimurium LPS than the PBS control after the second immunization (Fig. 4A and C), and the IgG 
levels induced by the vaccine strains SLT18 (pQK664) and SLT18 (pCZ1) were significantly higher than that of 
the vaccine strain SLT17 (pCZ1) (Fig. 4A). Furthermore, only the recombinant vaccine strains SLT17 (pCZ1) and 
SLT18 (pCZ1) induced a specific serum IgG or fecal IgA response against Salmonella Choleraesuis LPS after the 
second immunization, and the IgG or IgA level induced by SLT17 (pCZ1) was significantly higher than that of 
SLT18 (pCZ1) (Fig. 4B and C).
To determine whether each vaccine strain elicited bactericidal antibodies, we used the serum from each 
group at week 3 post-second immunization and measured the relative bactericidal activities against the homol-
ogous Salmonella Typhimurium strain S100 and the heterologous Salmonella Choleraesuis strain S340. The 
bacteria were incubated with 25% heat-inactivated serum plus active guinea pig complement or no complement 
for 1.5 h, and the relative survival was then calculated as the percent CFU in each serum with active complement 
compared to the CFU of the same serum with no complement. Salmonella O:4-specific and O:7-specific antisera 
were included as positive controls. As shown in Fig. 5A, the antibodies elicited by either the recombinant strains 
SLT17 (pCZ1) and SLT18 (pCZ1) or the control strains SLT17 (pQK664) and SLT18 (pQK664) were able to 
kill the homologous S100 strain at a similar level, which was significantly better than the antibodies from the 
PBS group. The ability of positive O:4-specific antisera to mediate killing was comparable to that of the antisera 
induced by the SLT17 (pCZ1), SLT18 (pQK664) and SLT18 (pCZ1) groups but better than that of the serum 
induced by SLT17 (pQK664) (Fig. 5A). Furthermore, the antibody from the SLT17 (pCZ1) and SLT18 (pCZ1) 
groups resulted in significant killing against the heterologous S340 strain, which was much better than that of 
the PBS group and comparable to that of the positive O:7-specific antisera (Fig. 5B). In contrast, no significant 
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Figure 2. Effects of heterologous O-antigen expression on Salmonella Typhimurium biological activities. (A) 
Swimming assay. SLT10 (pQK664), SLT12 (pQK664), SLT12 (pCZ1) and the two arabinose-regulated strains 
SLT16 (pQK664) and SLT16 (pCZ1) were grown in LB broth with or without 0.1% arabinose. Then, 6 μl of the 
bacterial suspension (approximately 1 × 106 CFU) was spotted onto the middle of LB plates containing 0.3% 
agar with or without arabinose, and the diameter of the colonies was measured 6 h after incubation. (B and C) 
Resistance to polymyxin and DOC. The same Salmonella Typhimurium strains described in A were cultured 
in LB broth with or without 0.1% arabinose. One-hundred microliters of the cell suspension (approximately 
1 × 106–5 × 106 CFU) was inoculated with or without 0.12 μg/ml polymyxin B (B) or 4 mg/ml DOC (C) for 1 h 
at 37 °C. The bacteria were diluted and plated onto LB plates, and the survival rate was calculated the following 
day. (D,E and F) Colonization. Groups of BALB/c mice (n = 4/group) were orally inoculated with 1 × 109 
CFU of each indicated strain. Viable bacteria were recovered from PP (D), liver (E) and spleen (F) 6 days after 
infection. The bacterial number in each tissue was calculated as log10 CFU/g. The asterisk above the error bar 
indicates significance compared to the SLT10 (pQK664) group. ***p < 0.001.
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killing against the heterologous S340 strain was observed in the control SLT17 (pQK664) or SLT18 (pQK664) 
groups. Notably, the relative survival of S340 in the SLT17 (pCZ1) group was significantly lower than that of the 
SLT18 (pCZ1) group (Fig. 5B), indicating that SLT17 (pCZ1) immunization induces enhanced serum bacteri-
cidal effects.
Figure 3. LPS phenotypes of the vaccine strains. LPS samples extracted from Salmonella Typhimurium 
wild-type S100 (lane 1), SLT17 (pQK664) (lane 2), SLT17 (pCZ1) (lane 3) and SLT18 (pQK664) grown with 
arabinose (lane 4) or without arabinose (lane 5), SLT18 (pCZ1) grown with arabinose (lane 6) or without 
arabinose (lane 7) and Salmonella Choleraesuis S340 (lane 8) were visualized by silver staining following PAGE. 
Each lane corresponds to LPS from 108 bacteria.
Figure 4. Antibody responses induced by the recombinant attenuated vaccines. (A and B) Serum IgG 
responses. Groups of BALB/c mice were immunized with 1 × 109 CFU of SLT17 (pQK664), SLT17 (pCZ1), 
SLT18 (pQK664), SLT18 (pCZ1) or PBS twice at an interval of 4 weeks. Serum samples were collected from 6 
mice from each group 3 weeks and 7 weeks after the first immunization. The serum IgG specific to Salmonella 
Typhimurium LPS (A) and Salmonella Choleraesuis LPS (B) was measured by quantitative ELISA in each 
group (C). Fecal IgA responses. The fecal samples were collected from 6 mice of each group 3 weeks after the 
second immunization. Fecal IgAs against Salmonella Typhimurium LPS and Salmonella Choleraesuis LPS 
were detected by indirect ELISA. The asterisk above the error bar indicates significance compared with the PBS 
control group. The asterisk above the line indicates significance between the two indicated groups. *p < 0.05. 
**p < 0.01. ***p < 0.001.
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All 12 mice in the SLT18 (pQK664), SLT17 (pCZ1) and SLT18 (pCZ1) immunized groups survived the 
Salmonella Typhimurium S100 challenge, suggesting 100% protection. In contrast, only 2 of 12 mice in the SLT17 
(pQK664) group survived the challenge, and all 12 mice of the PBS group succumbed to the challenge (Fig. 6A). 
In the presence of the Salmonella Choleraesuis S340 challenge, the SLT17 (pCZ1) immunization resulted in 
83% survival, which was better than the 50% survival observed for the SLT18 (pCZ1) group (Fig. 6B, log-rank 
test, p < 0.01). All of the mice in the control SLT17 (pQK664), SLT18 (pQK664) and PBS groups succumbed to 
the challenge (Fig. 6B). Thus, the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1) provided full 
protection against lethal homologous challenge and 83% and 50% heterologous protection against Salmonella 
Choleraesuis lethal challenge, respectively.
Discussion
NTS serovars Typhimurium, Enteritidis and Group C Salmonella are important causes of foodborne salmonel-
losis worldwide3. There is urgent need for an effective vaccine with broad serovar coverage for the prevention 
of salmonellosis in humans and animals. Although some types of vaccines, such as live attenuated vaccines and 
O-antigen-based conjugate vaccines, are in development37, there is no or only partial cross-protection achieved by 
these vaccines. Here, we developed two bivalent vaccines, SLT17 (pCZ1) and SLT18 (pCZ1), by recombinant expres-
sion of Salmonella Choleraesuis O-antigen (Group C1) in attenuated Salmonella Typhimurium strains. The reason 
for the selection of Salmonella Typhimurium as the vaccine vector rather than other serovars is that Salmonella 
Figure 5. Serum bactericidal assay. Salmonella Typhimurium S100 (A) or Salmonella Choleraesuis S340 (B) 
was incubated with the serum collected from each immunized group at 3 weeks post-second immunization. 
Active guinea pig complement was added to or omitted from the mixture. The relative survival was calculated at 
1.5 h post-incubation. The asterisk above the error bar indicates significance compared to the PBS control group. 
The asterisk above the line indicates significance between the two indicated groups. *p < 0.05. ***p < 0.001.
Figure 6. Survival rates after a lethal oral challenge with Salmonella Typhimurium S100 (A) or Salmonella 
Choleraesuis S340 (B) are shown. The immunized mice (n = 12/group) were challenged with at least 100 × LD50 
of virulent S100 or virulent S340. Mortality was recorded daily for 15 days.
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Typhimurium is the most well-studied NTS serovar, and a set of recombinant vaccine technologies has been devel-
oped for this serovar28. Here, we used the Asd-based balanced-lethal vector-host system32 to maintain the expression 
of the heterologous O-antigen and an arabinose-dependent regulated attenuation system34 to achieve expression of 
the homologous O-antigen dependent on exogenously supplied arabinose during in vitro growth.
O-antigens are characterized as immunodominant and protective antigens in Salmonella as well as in sev-
eral other infectious bacteria. Recombinant attenuated Salmonella vaccines expressing Shigella sonnei O-antigen 
or Burkholderia mallei O-antigen have been constructed and exhibit protection against lethal challenge38, 39. 
Surprisingly, a similar strategy has not been used for the development of bivalent or multivalent Salmonella vac-
cines. A potential advantage of O-antigen-based Salmonella vaccines is that they should offer cross-protection 
against other serovars within the same serogroup because all serovars in one serogroup express the same dom-
inant O-antigen epitopes24 (group C1 serovars all express O:6,7 antigen13). Antigen level is an important factor 
influencing the magnitude of the immune response. To maximize the expression of the heterologous Salmonella 
Choleraesuis O-antigen, synthesis of the Salmonella Typhimurium O-antigen (Group B1) was blocked by deletion 
of either the rfbP gene or the whole O-antigen gene cluster. The pCZ1 plasmid containing the whole O-antigen 
gene cluster of Salmonella Choleraesuis was then introduced into the rough mutant strains. This strategy for gene 
deletion and introduction was based on the finding that the Group C1 O-antigen and its gene cluster are quite 
distinct from the Group B1 O-antigen13. As expected, the two recombinant strains, SLT11 (pCZ1), with deletion 
of the rfbP gene, and SLT12 (pCZ1), with deletion of the whole Salmonella Typhimurium O-antigen gene clus-
ter, efficiently expressed the heterologous O-antigen, whereas unexpectedly, SLT11 (pCZ1) also expressed the 
homologous O-antigen, as indicated by the immunoblotting results (Fig. 1B and C, lanes 3 and 5). Because the 
genes for initiating O-unit synthesis in Groups C1 and B1 were different (wecA for C1 O-antigen and rfbP for B1 
O-antigen)13 and the homologous O-antigen expression was not observed in SLT11 (pQK664) (Fig. 1B and C, 
lane 2), it was impossible to express the complete Salmonella Typhimurium O-antigen structure in SLT11 
(pCZ1). According to the O-antigen structures and the required glycosyltransferase genes between Groups B1 
and C113, we speculate that a branching sugar (abequose) was synthesized and attached to D-mannose in the 
backbone of heterologous O-antigen in SLT11 (pCZ1) by the abe and wbaV genes, which reside in the Salmonella 
Typhimurium O-antigen gene cluster, conferring immunodominant epitope 4 specificity15, which can be recog-
nized by the Salmonella O:4 specific antisera that was employed. In contrast, the band specifying the Salmonella 
Typhimurium O-antigen was not observed in SLT12 (pCZ1) (Fig. 1B, lane 5) because the entire Salmonella 
Typhimurium O-antigen gene cluster was deleted. Therefore, it was possible that the SLT11 (pCZ1) expressed the 
O:4 epitope rather than the complete homologous O-antigen. Given that the antibodies specific to the homolo-
gous O-antigen play important roles in immune protection against Salmonella Typhimurium31, we constructed 
another recombinant strain, SLT16 (pCZ1), in which the heterologous O-antigen and complete homologous 
O-antigen were expressed when arabinose was available; the heterologous O-antigen and short-length homolo-
gous (probably the O:4 epitope) were expressed when grown without arabinose, similar to that displayed by the 
SLT11 (pCZ1) (Fig. 1D,E and F). Because arabinose is not present in tissues upon the invasion of Salmonella into 
the gut-associated lymphoid tissue40, the expression of complete homologous O-antigen was activated before the 
bacteria invaded these cells and ceased after invasion due to cell division.
The O-antigen is an important virulence factor, which is involved in bacterial motility, colonization and 
survival in the host29, 31. Loss of the entire O-antigen attenuates swimming motility and intestinal colonization 
and renders bacteria highly susceptible to antimicrobial agents. In our constructed recombinant strains SLT12 
(pCZ1) and SLT16 (pCZ1), the wild-type Salmonella Typhimurium O-antigen was replaced by the heterologous 
O-antigen or the chimeric O-antigen. We determined whether the altered O-antigen structures influenced swim-
ming motility, resistance to polymyxin B and DOC and colonization of Salmonella Typhimurium. The results 
showed that none of the examined phenotypes were affected by heterologous O-antigen expression (Fig. 2), 
indicating that O-antigen expression itself, rather than O-antigen variety, was vital for these Salmonella pheno-
types. Additionally, the rough strains SLT12 (pQK664) and SLT16 (pQK664) (grown without arabinose) showed 
decreased swimming and increased sensitivity to polymyxin B and DOC, which was consistent with previous 
studies29. Surprisingly, no detectable bacteria were recovered from the PP, liver or spleen tissues 6 days after oral 
inoculation with STL12 (pQK664) (Fig. 2D,E and F). The attenuated colonization is consistent with previous 
results showing that deletion of genes responsible for O-antigen synthesis, such as rfaH and rfbP, results in rough 
LPS and decreased but not undetectable colonization31. This result suggested that deletion of the whole O-antigen 
cluster further attenuates colonization.
Next, the crp and cya genes, which have been identified as the mutation targets of live vaccines41, 42, were 
deleted from the recombinant and control strains for attenuation and to evaluate the immunogenicity and pro-
tective efficacy. The derived vaccine strains showed similar LPS phenotypes as their parent strains (Figs 3 and 
S1), suggesting that deletions of crp and cya do not affect LPS structure, in agreement with previous reports43. 
Both the recombinant vaccine strains SLT17 (pCZ1) and SLT18 (pCZ1) induced significantly higher serum 
IgG and fecal IgA responses against the homologous and heterologous LPS than the PBS control at 3 weeks 
post-second immunization (Fig. 4). The bactericidal effects exerted by sera induced by the two recombinant 
vaccine strains were comparable to those of the homologous S100 strain with the O:4-specific antisera (Fig. 5A) 
and the heterologous S340 strain with the O:7-specific antisera (Fig. 5B). The control strain SLT17 (pQK664) did 
not produce antibodies immunoreactive to either the homologous or heterologous LPS (Fig. 4), possibly due to 
a combination of the rough LPS phenotype (Supplementary Fig. S1) and undetectable colonization in mouse 
tissues (Supplementary Fig. S2); however, the serum from the SLT17 (pQK664)-immunized group mediated 
significantly increased killing of the homologous S100 strain compared with the PBS group. Combined with 
the finding that immunization with SLT17 (pQK664) induced low-level homologous protection (Fig. 6A), this 
result suggested that SLT17 (pQK664) was still immunogenic and induced a specific antibody response against 
other Salmonella Typhimurium antigens with high immunogenicity rather than the rough LPS. Furthermore, 
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the other control strain, SLT18 (pQK664), which expressed the homologous O-antigen only when arabinose was 
present during in vitro growth, produced significant serum IgG and fecal IgA specific to the homologous LPS 
but not to the heterologous LPS (Fig. 4). In addition, serum produced from SLT18 (pQK664) exhibited killing 
against the homologous S100 strain but not the heterologous S340 strain (Fig. 5A and B), suggesting that there 
was less cross-immunoreactivity between serum antibodies specific to Salmonella Typhimurium and Salmonella 
Choleraesuis. However, SLT17 (pCZ1), which expressed only the heterologous O-antigen, elicited detectable 
anti-homologous LPS IgG and IgA (Fig. 4A and C), similar to the phenomenon that was observed in immu-
nization experiments based on the Salmonella Typhimurium ΔrfbP mutant with a rough LPS phenotype31. We 
speculate that the antibodies detected were in response to the core region or lipid A of Salmonella Typhimurium 
LPS, which were contained in the ELISA coating antigens.
The potent antibody responses specific to the heterologous O-antigen and its functional bactericidal effects 
against Salmonella Choleraesuis induced by the two recombinant vaccines SLT17 (pCZ1) and SLT18 (pCZ1) 
demonstrated the high immunogenicity of the delivered heterologous O-antigen. To determine whether the 
induced antibody responses conferred heterologous protection, the protective efficacy was further investigated. 
The vaccine strains SLT17 (pCZ1), SLT18 (pQK664) and SLT18 (pCZ1) provided full homologous protection 
against lethal challenge with Salmonella Typhimurium (Fig. 6A), which was in line with the previous vaccine stud-
ies based on the crp/cya mutant and validated the immunization and challenge conditions of our study. The full 
homologous protection conferred by the SLT17 (pCZ1), which did not express the homologous O-antigen, was in 
line with the finding observed in previous studies, which showed that attenuated Salmonella Typhimurium ΔrfaH 
or ΔrmlB mutant with rough LPS phenotypes also exhibited protection to homologous lethal challenge30, 36. 
Combined with the finding that the serum induced by SLT17 (pCZ1) exhibited significant bactericidal effects 
to the homologous S100 strain, the result suggested that the O-antigen-mediated antibody response was not 
indispensable for preventing Salmonella infections, and immune responses specific for other Salmonella antigens, 
such as OMPs, support the efficacy of these live Salmonella vaccines with rough LPS phenotypes36. In contrast, the 
control SLT17 (pQK664) strain mediated inefficient homologous protection (Fig. 6A), which is likely due to the 
undetectable colonization (Supplementary Fig. S2) and the resulting poor immunogenicity. In comparison with 
the full homologous protection provided by SLT18 (pQK664), no heterologous protection was observed in the 
SLT18 (pQK664) control groups (Fig. 6B), indicating little cross-protection between Salmonella Typhimurium 
and Salmonella Choleraesuis. This finding is in agreement with the corresponding poor cross-immunoreactivity 
of serum antibodies between Salmonella Typhimurium and Salmonella Choleraesuis. Furthermore, the recombi-
nant vaccines SLT17 (pCZ1) and SLT18 (pCZ1) resulted in 83% and 50% heterologous protection against lethal 
challenge with Salmonella Choleraesuis, respectively. The differences in the protection efficacy was correlated 
with differences in immunogenicity: SLT17 (pCZ1) immunization stimulated higher serum IgG and fecal IgA 
responses against the heterologous O-antigen and resulted in better killing of Salmonella Choleraesuis than SLT18 
(pCZ1). We speculate that the higher amount of heterologous O-antigen expressed by SLT17 (pCZ1) than SLT18 
(pCZ1) (Fig. 3) resulted in the differences in immunogenicity and protective efficacy.
Because only partial heterologous protection was achieved by the developed recombinant vaccines, consid-
erable efforts should be made to improve the protective efficacy in future studies. One strategy is to increase 
the expression level of heterologous O-antigen, which might be achieved by constructing a new recombinant 
plasmid with a higher copy number, such as a pBR322-derived plasmid, or inserting the Salmonella Choleraesuis 
O-antigen gene cluster into a bacterial chromosome to replace the Salmonella Typhimurium O-antigen gene clus-
ter, resulting in stable expression of heterologous O-antigen initiated by the native promoter39, 44. The other strat-
egy is the construction of more effective recombinant Salmonella vectors via well-developed regulated delayed 
attenuation45. Importantly, our study provides a new approach: heterologous expression of O-antigen to develop 
multivalent Salmonella vaccines. Some issues remain to be addressed in subsequent studies, and these include 
whether Salmonella can simultaneously express two or more types of heterologous O-antigens, and ensuring the 
expression of sufficient amounts of heterologous O-antigens to stimulate a protective immune response when 
multiple O-antigens are expressed at the same time. Nevertheless, a mixture of several recombinant Salmonella 
strains, each of which express only one type of heterologous O-antigen, can be used as multivalent vaccine can-
didates and subjected to evaluations of immunogenicity and heterologous protection efficacy in future studies.
In summary, we developed two bivalent vaccines, SLT17 (pCZ1) and SLT18 (pCZ1), by stable recombinant 
expression of the heterologous Salmonella Choleraesuis O-antigen in attenuated Salmonella Typhimurium. 
Expression of the heterologous O-antigen had no adverse effects on bacterial swimming, resistance to poly-
myxin B and DOC or colonization. Immunization with SLT17 (pCZ1) and SLT18 (pCZ1) provided full pro-
tection against Salmonella Typhimurium infection and exhibited improved cross-protection against Salmonella 
Choleraesuis infection. The ability of the two vaccines to induce strong antibody-mediated immunity represents 
a promising step towards the development of live multivalent vaccines with broad serovar coverage.
Methods
Ethics statement. All animal experiments in this study were performed in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and 
Technology of China. All animal procedures were approved by the Animal Ethics Committee of the Sichuan 
Agricultural University.
Bacterial strains, plasmids and growth conditions. The bacterial strains and plasmids utilized in this 
study are described in Table 1. Salmonella enterica and E. coli were grown in Luria-Bertani (LB) broth or on LB 
agar with or without 0.1% arabinose. When required, antibiotics and diaminopimelic acid (DAP) were added 
to the medium at the following concentrations: kanamycin, 50 μg/ml; ampicillin, 100 μg/ml; chloramphenicol, 
25 μg/ml; DAP, 50 μg/ml. LB agar containing 10% sucrose was used for sacB gene-based counter selection in the 
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allelic exchange experiments. The transformation of Salmonella Typhimurium was performed via electropora-
tion. Transformants were selected on LB agar plates containing the appropriate antibiotics.
Plasmids and mutant strain construction. The primers used to delete the rfbP gene have been described 
previously31. Other primers used in this study are listed in Supplementary Table S2. The introduction of gene 
mutations in Salmonella Typhimurium was carried out by allelic exchange using the suicide T-vector pYA4278 
as previously described31. For deletion of the asd gene, the primers Dasd-1F/Dasd-1R and Dasd-2F/Dasd-2R 
were used to amplify approximately 450 bp upstream and downstream segments from the S100 genome, respec-
tively. The two fragments were then joined by PCR using primers Dasd-1F and Dasd-2R. The PCR product 
was then ligated to AhdI-digested pYA4278 to generate plasmid pCZ2, which was introduced into Salmonella 
Typhimurium S100 for the asd deletion mutation. The selection and characterization of the asd mutants were 
carried out by PCR using the primers Dasd-1F and Dasd-2R. The same method was applied to delete the rfbP, 
pagL, crp and cya genes and the whole O-antigen gene cluster (rmlB-rfbP). To construct the arabinose-regulated 
mutants, the primers rfbP-F and rfbP-R were used to amplify the rfbP gene from the S100 genome, and the PCR 
product was then inserted into plasmid pSS24536 between the NheI and KpnI sites, generating the pCZ10 plas-
mid. The primers TT-F and rfbP-R were then used to amplify the TTaraCPBAD rfbP fragment from pCZ10. The 
product was inserted into NotI and SbfI double-digested pCZ5 (pYA4278-ΔpagL), generating the plasmid pCZ8, 
which was introduced into the strain SLT13 (Δasd ΔrfbP ∆pagL) for TTaraCPBAD rfbP insertion in the pagL gene 
site, generating the strain SLT16 (Δasd ΔrfbP ∆pagL::TT araC PBAD rfbP).
To express the heterologous O-antigen in Salmonella Typhimurium mutant strains, the recombinant plas-
mid pCZ1 was constructed. The primer pair C1-O-antigen-F and C1-O-antigen-R was used to amplify the 
whole O-antigen gene cluster (8870 bp) of Salmonella Choleraesuis from the S340 genome, and the primers 
pQK664-C1F and pQK664-C1R were used to amplify a DNA fragment containing the pSC101 origin, asd gene 
cassette, TIT2 terminator, Ptrc promoter and kanamycin-resistance cassette from the plasmid pQK66433. Next, 
the two PCR products were joined by the Gibson Assembly Kit (NEB, Beverley, MA, USA), generating the plas-
mid pCZ1. Then, the pCZ1 or the control plasmid pQK664 was transformed into Salmonella Typhimurium 
SLT11 (Δasd ΔrfbP), SLT12 (Δasd ΔrmlB-rfbP) and SLT16 (Δasd ΔrfbP ∆pagL::TT araCPBAD rfbP), generating 
the three recombinant strains SLT11 (pCZ1), SLT12 (pCZ1) and SLT16 (pCZ1) and the three control strains 
SLT11 (pQK664), SLT12 (pQK664) and SLT16 (pQK664).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), silver staining and 
Western immunoblotting. To confirm the expression of Salmonella Typhimurium and Salmonella 
Choleraesuis O-antigens, SDS-PAGE, silver staining and Western blot analyses were performed as previously 
described46, 47. In brief, each bacterial strain was cultured and adjusted to an OD600 = 1.0. Two microliters of each 
suspension were then centrifuged and resuspended in 100 ml of lysis buffer containing proteinase K. Ten micro-
liters of the solution were then separated by SDS-PAGE in a 12% (w/v) acrylamide gel and then silver-stained 
Strains or plasmids Description Source
Plasmids
pQK664 Derived from pYA3337, Asd+ Ptrc pSC101 origin, kanr 33
pSS246 pYA3700-rfbB 36
pCZ1 Asd+, pSC101 origin, Ptrc-O-antigen gene cluster of Salmonella Choleraesuis This work
pYA4278 pRE112 derivative, sacB mobRP4 R6K ori Cmr 31
pCZ2 pYA4278-Δasd This work
pCZ3 pYA4278-ΔrfbP This work
pCZ4 pYA4278-ΔrmlB-rfbP This work
pCZ5 pYA4278-ΔpagL This work
pCZ6 pYA4278-Δcrp This work
pCZ7 pYA4278-Δcya This work
pCZ8 pCZ5-TTaraC PBAD rfbP This work
pCZ10 pSS246-rfbP This work
Strains
S100 Wild-type Salmonella Typhimurium 51
SLT10 S100 Δasd38 This work
S340 Salmonella Choleraesuis, wild-type virulent 36
SLT11 SLT10 ΔrfbP39 This work
SLT12 SLT10 Δ(rmlB-rfbP)24 This work
SLT13 SLT10 ΔrfbP39 ∆pagL32 This work
SLT16 SLT10 ΔrfbP39 ∆pagL32::TT araC PBAD rfbP This work
SLT17 SLT12 Δcrp33 Δcya33 This work
SLT18 SLT16 Δcrp33 Δcya33 This work
Table 1. Bacterial strains and plasmids used in this study.
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or subjected to Western immunoblotting with Salmonella O:4- or O:7-specific antisera diluted to 1:200 (Tianjin 
Biochip Corporation, Tianjin, China).
Detection of bacterial biological activities. The bacteria were grown to an OD600 = 0.8–0.9 in LB broth 
with or without 0.1% arabinose, harvested and resuspended in LB. For the swimming assay, 6 μl of a bacterial sus-
pension (approximately 1 × 106 CFU) was spotted onto the middle of LB plates containing 0.3% agar with or without 
arabinose. The diameter of the colonies was measured 6 h after incubation at 37 °C. To measure the resistance to 
polymyxin B and DOC, 100 μl of the cell suspension (approximately 1 × 106–5 × 106 CFU) was inoculated with or 
without polymyxin B at a final concentration of 0.12 μg/ml or DOC at a final concentration of 4 mg/ml for 1 h at 
37 °C. The bacteria were diluted to the appropriate concentration and plated onto LB plates. The survival rate was cal-
culated as the CFU per ml of the polymyxin B- or DOC-treated group divided by the CFU of the non-treated group.
Determination of bacterial colonization and virulence (LD50) in mice. Six-week-old female 
BALB/c mice were obtained from Dashuo Experimental Animal Ltd. (Chengdu, China). The mice were accli-
mated for 7 days after arrival before the experiments were initiated. The colonization and the LD50 of Salmonella 
Typhimurium strains were measured as previously described31. In brief, for the colonization experiments, BALB/c 
mice were inoculated orally with 1 × 109 CFU of each strain. Six days after oral inoculation, tissues, including PP, 
spleen and liver, were collected from three animals, weighed and homogenized in 1 ml of PBS. Then, appropriate 
dilutions were plated onto MacConkey agar or LB agar to determine the number of viable bacteria. The coloniza-
tion value was calculated as CFU per gram of tissue (CFU/g). For determination of the LD50, stepwise increasing 
doses of Salmonella Typhimurium strains were orally inoculated into groups of BALB/c mice. The mortality of 
the animals was monitored over a period of 1 month after infection. The LD50 was calculated using the method 
of Reed and Muench.
Immunization and challenge. The Salmonella vaccine strains SLT17 (pQK664), SLT17 (pCZ1), SLT18 
(pQK664) and SLT18 (pCZ1) were grown statically overnight in LB broth (0.1% arabinose was added for culture 
of the arabinose-regulated vaccine strains) at 37 °C. The next day, the overnight culture was diluted 1:100 into 
100 ml of LB broth (0.1% arabinose was added for culture of the arabinose-regulated vaccine strains) and grown 
with shaking at 37 °C to an OD600 value of 0.8 to 0.9. The cells were harvested by centrifugation and resuspended 
in 1 ml of phosphate buffer saline (PBS). Groups of mice (12 mice per group) were orally inoculated with 20 µl of 
PBS containing 1 × 109 CFU of each strain or with PBS without bacteria twice at an interval of 4 weeks. The serum 
was collected three weeks after each immunization. The feces used for the analysis of fecal IgA were collected 
three weeks after the second immunization and suspended in 100 µl of PBS, and the supernatant was collected 
after centrifugation at 12,000 × g and 4 °C for 5 min. One month post-second immunization, mice in each immu-
nization group were orally challenged with at least 100 × LD50 of the Salmonella Typhimurium virulent strain 
S100 and the Salmonella Choleraesuis virulent strain S340, respectively. The challenged mice were monitored, and 
mortality was recorded daily for 15 days.
ELISA. Salmonella Typhimurium LPS was purchased from Sigma (St. Louis, MO, USA), and Salmonella 
Choleraesuis LPS was extracted and purified as described48. The serum IgG concentration was determined by 
quantitative ELISA, and the fecal IgA was measured by indirect ELISA, as previously described36, 49. In brief, a 
96-well ELISA microplate was coated with 100 ng/well LPS or 100 ng/well goat anti-mouse Ig(H + L) (BD, San 
Diego, CA, USA) and then blocked with 2% BSA (BD) after overnight incubation at 4 °C. For the detection of 
serum IgG, the serum samples were diluted to 1:100 in PBS containing 2% BSA, and 100 μl of this solution was 
added to the LPS-coated wells in duplicate. Meanwhile, 100 μl of mouse IgG (BD) with serial two-fold dilutions 
from 0.5 mg/ml were added to the goat anti-mouse Ig(H + L)-coated wells for the standard curve. For the detec-
tion of fecal IgA, the fecal supernatant was diluted 1:4 and added to the LPS-coated wells in duplicate. After 1 h 
of incubation at 37 °C, 100 μl of biotinylated goat anti-mouse IgG (Southern Biotech, Birmingham, AL, USA) or 
biotinylated goat anti-mouse IgA (Southern Biotech) and 100 μl of streptavidin-alkaline phosphatase conjugate 
(Southern Biotech) were added to each well sequentially, followed by p-nitrophenylphosphate substrate in dietha-
nolamine buffer. Finally, the plate was read at 405 nm using a microplate reader (Bio-Rad Laboratories, California, 
USA). The standard curve was drawn using Curve Expert (Hyams DG, Starkville, MS, USA), and the concentra-
tion of serum IgG antibodies was calculated according to the standard curve.
Serum bactericidal assay. The serumcollected from mice of each immunized group at week 3 post-second 
immunization was pooled for the serum bactericidal assay as described previously50. The commercial Salmonella 
O:4-specific and O:7-specific antisera were used as positive controls. All serum samples were heated at 56 °C 
for 30 min to inactivate endogenous complement. Salmonella Typhimurium S100 or Salmonella Choleraesuis 
S340 were grown in LB medium to log phase and were diluted in SBA buffer (50 mM phosphate, 0.041% 
MgCl2·6H2O, 33 mg/ml CaCl2, 0.5% BSA) to approximately 3 × 103 CFU/ml. The bacteria were incubated with 
25% heat-inactivated serum supplemented with or without active guinea pig complement (Sigma) for 1.5 h. The 
relative survival was calculated as the percent CFU counted in each pooled serum with active complement com-
pared to the CFU of the same serum with no complement. Each sample and control was tested in triplicate.
Statistical analysis. The data are shown as the means ± SD. One-way ANOVA followed by Tukey’s 
multiple-comparison test were used to evaluate statistical significance. A probability value of P < 0.05 was con-
sidered statistically significant. The survival curve post-challenge was analyzed using the log-rank test. All in vitro 
experiments were repeated at least three times, and the in vivo experiments were repeated at least twice.
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Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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